![](https://www.diabetesnews.com/wp-content/uploads/2016/05/Insulin_Nation_Metformin_Type_1_Diabetes_Testing_Prevention_620px-150x150.jpg)
Over a one-year study, glycemic control was improved and body weight and blood pressure were reduced with Invokana® (canagliflozin, Janssen) as add-on therapy to metformin in patients with type 2 diabetes, according to a presentation at AACE.
Over a one-year study, glycemic control was improved and body weight and blood pressure were reduced with Invokana® (canagliflozin, Janssen) as add-on therapy to metformin in patients with type 2 diabetes, according to a presentation at AACE.